Welcome to our dedicated page for InMed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on InMed Pharmaceuticals stock.
InMed Pharmaceuticals Inc. reports developments as a pharmaceutical company developing proprietary small-molecule drug candidates for diseases with high unmet medical needs. Its pipeline targets CB1 and CB2 receptors and includes INM-901 for Alzheimer's disease, along with ocular and dermatological programs.
Recurring updates cover financial results, business progress, preclinical and regulatory disclosures, shareholder voting matters, capital actions, Nasdaq listing compliance, and changes affecting BayMedica, its wholly owned subsidiary historically associated with rare cannabinoid commercial activities.
InMed Pharmaceuticals (NASDAQ: INM) received a Nasdaq notice dated March 27, 2026 that the closing bid price was below the $1.00 minimum during the February 11, 2026–March 26, 2026 period.
The company has a 180-calendar day cure period to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days; trading will continue under the symbol INM.
InMed Pharmaceuticals (NASDAQ: INM) reported preclinical data showing INM-901 reduced neuroinflammation in two human 3D brain organoid models, including a Stem Pharm Alzheimer's disease model.
Findings showed dose-dependent reductions in IL-6 and IL-8, aligned with prior in vivo and ex vivo results, and support a planned pre-IND meeting in Q3 2026 and a targeted IND/Phase 1 start in 2027.
InMed (NASDAQ: INM) outlines 2026 pharmaceutical development priorities, focusing on advancing INM-901 toward a pre-IND meeting in Q3 2026 and IND-enabling studies with a target to submit an IND and initiate a Phase 1 Alzheimer’s trial in 2027. Key preclinical findings show anti-neuroinflammatory effects, neuroprotection, neuritogenesis, behavioral gains, and oral bioavailability in large animals. The company also plans a pre-IND meeting for INM-089 in Q4 2026 and continues formulation, scale-up, and regulatory planning for both programs.
InMed Pharmaceuticals (NASDAQ: INM) announced BayMedica LLC will wind down its commercial operations due to regulatory uncertainty from H.R. 5371, which could prohibit parts of BayMedica's cannabinoid commercial business if effective November 12, 2026. BayMedica expects to substantially complete the exit before June 30, 2026.
The company will focus exclusively on advancing its pharmaceutical pipeline, notably INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration, toward IND filings and initial human trials. Estimated one-time employee-related costs total approximately $550,000 plus $120,000 of additional expenditures through fiscal year end.
InMed (NASDAQ: INM) reported Q2 FY2026 results for the quarter ended December 31, 2025 and provided a pipeline update. Key developments: INM-901 completed large-animal oral PK studies with robust bioavailability and no adverse neural effects; INM-089 showed functional improvements in dry AMD models. Financials: cash of $7.0M, Q2 net loss of $2.03M, BayMedica revenue down 26% YoY to $0.8M. The company expects cash to fund operations into Q4 calendar 2026 and flagged material legislative risk from H.R. 5371 affecting BayMedica.
InMed Pharmaceuticals (NASDAQ: INM) reported results from its annual general and special meeting held December 17, 2025.
A total of 993,491 common shares (≈35.43% of 2,804,186 outstanding) were represented. All five director nominees were elected with roughly 81.9%–82.1% votes for. Shareholders approved CBIZ CPAs P.C. as auditors and approved the potential issuance of 20% or more of common shares under the amended Standby Equity Purchase Agreement with YA II PN, Ltd. The company filed the voting results on SEDAR+ on December 17, 2025.
InMed (NASDAQ: INM) said on December 12, 2025 that provisions in H.R. 5371 (the "Act") could materially and negatively affect the commercial business of subsidiary BayMedica if those provisions come into force on November 12, 2026.
The company said the Act in its current form would prohibit certain aspects of BayMedica's commercial operations and its inventory of rare, non‑intoxicating cannabinoids, and that BayMedica is evaluating alternative supply‑chain options while continuing normal operations.
InMed emphasized the Act does not affect its core pharmaceutical programs and reaffirmed progress on INM‑901 for Alzheimer's disease and INM‑089 for age‑related macular degeneration. The company noted uncertainty whether the relevant Act provisions will take effect or be amended and pointed investors to its SEC filings for details on BayMedica's contribution to consolidated results.
InMed (NASDAQ: INM) reported Q1 fiscal 2026 results for the quarter ended September 30, 2025 and provided a business update on its drug programs.
Key metrics: cash and cash equivalents $9.3M (down from $11.1M June 30, 2025), BayMedica revenue $1.12M (down 11% year-over-year), R&D $0.58M, and net loss $1.73M. Management expects cash to fund operations into Q4 calendar 2026 depending on revenues and expense timing.
Program highlights: INM-901 advanced preclinical work with a 7-month 5xFAD mouse study presented at AAIC and IND-enabling and CMC activities underway; INM-089 continues preclinical evaluation for dry AMD.
InMed Pharmaceuticals (NASDAQ: INM) announced the immediate appointment of John Bathery to its Board of Directors, effective October 16, 2025.
Bathery brings more than 30 years of pharmaceutical experience, including 15+ years in corporate development, and has led transactions exceeding $60 billion. The company said his expertise will support advancement of INM-901 for Alzheimer’s and INM-089 for age-related macular degeneration toward clinical readiness and partnership exploration.
The release also said Bryan Baldasare will not stand for re-election at the December 18, 2025 annual meeting.
InMed Pharmaceuticals (NASDAQ: INM) appointed Neil Klompas, CPA, CA to its board effective October 9, 2025.
Klompas brings 30+ years of healthcare and biotech experience, including roles as President and COO and earlier CFO at Zymeworks, where he helped scale the company and led its 2017 IPO. He is currently CEO of Augerex Life Science and serves on the boards of NervGen Pharma and HTuO Biosciences. InMed highlighted Klompas’ operational, financial and capital-markets expertise as supportive for advancing its pipeline; Klompas praised InMed's science and cited INM-901 data as a draw.